|
1
|
Bentires-Alj M, Paez JG, David FS, et al:
Activating mutations of the Noonan syndrome-associated SHP2/PTPN11
gene in human solid tumors and adult acute myelogenous leukemia.
Cancer Res. 64:8816–8820. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ben-Jonathan N, Liby K, McFarland M and
Zinger M: Prolactin as an autocrine/paracrine growth factor in
human cancer. Trends Endocrinol Metab. 13:245–250. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chan G, Kalaitzidis D and Neel BG: The
tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis
Rev. 27:179–192. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinelli S, Carta C, Flex E, et al:
Activating PTPN11 mutations play a minor role in pediatric and
adult solid tumors. Cancer Genet Cytogenet. 166:124–129. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miyamoto D, Miyamoto M, Takahashi A,
Yomogita Y, Higashi H, Kondo S and Hatakeyama M: Isolation of a
distinct class of gain-of-function SHP-2 mutants with oncogenic
RAS-like transforming activity from solid tumors. Oncogene.
27:3508–3515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grossmann KS, Rosario M, Birchmeier C and
Birchmeier W: The tyrosine phosphatase Shp2 in development and
cancer. Adv Cancer Res. 106:53–89. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chan RJ and Feng GS: PTPN11 is the first
identified proto-oncogene that encodes a tyrosine phosphatase.
Blood. 109:862–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Serra V, Scaltriti M, Prudkin L, et al:
PI3K inhibition results in enhanced HER signaling and acquired ERK
dependency in HER2-overexpressing breast cancer. Oncogene.
30:2547–2557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tartaglia M, Mehler EL, Goldberg R, et al:
Mutations in PTPN11, encoding the protein tyrosine phosphatase
SHP-2, cause Noonan syndrome. Nat Genet. 29:465–468. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Edouard T, Combier JP, Nedelec A, et al:
Functional effects of PTPN11 (SHP2) mutations causing LEOPARD
syndrome on epidermal growth factor-induced phosphoinositide
3-kinase/AKT/glycogen synthase kinase 3beta signaling. Mol Cell
Biol. 30:2498–2507. 2010. View Article : Google Scholar
|
|
11
|
Masunaga R, Kohno H, Dhar DK, et al:
Cyclooxygenase-2 expression correlates with tumor
neovascularization and prognosis in human colorectal carcinoma
patients. Clin Cancer Res. 6:4064–4068. 2000.PubMed/NCBI
|
|
12
|
Zhou X, Coad J, Ducatman B and Agazie YM:
SHP2 is up-regulated in breast cancer cells and in infiltrating
ductal carcinoma of the breast, implying its involvement in breast
oncogenesis. Histopathology. 53:389–402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong Q, Siminovitch KA, Fialkow L,
Fukushima T and Downey GP: Negative regulation of myeloid cell
proliferation and function by the SH2 domain-containing tyrosine
phosphatase-1. J Immunol. 162:3220–3230. 1999.PubMed/NCBI
|
|
14
|
Agarwal R, D’Souza T and Morin PJ:
Claudin-3 and claudin-4 expression in ovarian epithelial cells
enhances invasion and is associated with increased matrix
metalloproteinase-2 activity. Cancer Res. 65:7378–7385. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Frearson JA and Alexander DR: The
phosphotyrosine phosphatase SHP-2 participates in a multimeric
signaling complex and regulates T cell receptor (TCR) coupling to
the Ras/mitogen-activated protein kinase (MAPK) pathway in Jurkat T
cells. J Exp Med. 187:1417–1426. 1998. View Article : Google Scholar
|
|
16
|
Hadari YR, Kouhara H, Lax I and
Schlessinger J: Binding of Shp2 tyrosine phosphatase to FRS2 is
essential for fibroblast growth factor-induced PC12 cell
differentiation. Mol Cell Biol. 18:3966–3973. 1998.PubMed/NCBI
|
|
17
|
Carver KC, Piazza TM and Schuler LA:
Prolactin enhances insulin-like growth factor I receptor
phosphorylation by decreasing its association with the tyrosine
phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem.
285:8003–8012. 2010. View Article : Google Scholar
|
|
18
|
Zhou XD and Agazie YM: Inhibition of SHP2
leads to mesenchymal to epithelial transition in breast cancer
cells. Cell Death Differ. 15:988–996. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhou X and Agazie YM: Molecular mechanism
for SHP2 in promoting HER2-induced signaling and transformation. J
Biol Chem. 284:12226–12234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tartaglia M, Niemeyer CM, Fragale A, et
al: Somatic mutations in PTPN11 in juvenile myelomonocytic
leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat
Genet. 34:148–150. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Eklund EA, Jalava A and Kakar R: PU.1,
interferon regulatory factor 1, and interferon consensus
sequence-binding protein cooperate to increase gp91(phox)
expression. J Biol Chem. 273:13957–13965. 1998. View Article : Google Scholar
|
|
22
|
Bouyain S and Watkins DJ: Identification
of tyrosine phosphatase ligands for contactin cell adhesion
molecules. Commun Integr Biol. 3:284–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang S, Yu WM, Zhang W, McCrae KR, Neel BG
and Qu CK: Noonan syndrome/leukemia-associated gain-of-function
mutations in SHP-2 phosphatase (PTPN11) enhance cell migration and
angiogenesis. J Biol Chem. 284:913–920. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tartaglia M, Kalidas K, Shaw A, et al:
PTPN11 mutations in Noonan syndrome: molecular spectrum,
genotype-phenotype correlation, and phenotypic heterogeneity. Am J
Hum Genet. 70:1555–1563. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tartaglia M, Martinelli S, Iavarone I, et
al: Somatic PTPN11 mutations in childhood acute myeloid leukaemia.
Br J Haematol. 129:333–339. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen H, Pimienta G, Gu Y, et al: Proteomic
characterization of Her2/neu-overexpressing breast cancer cells.
Proteomics. 10:3800–3810. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nijsten T, Colpaert CG, Vermeulen PB,
Harris AL, Van ME and Lambert J: Cyclooxygenase-2 expression and
angiogenesis in squamous cell carcinoma of the skin and its
precursors: a paired immunohistochemical study of 35 cases. Br J
Dermatol. 151:837–845. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Van IC, Rahner C and Anderson JM:
Regulated expression of claudin-4 decreases paracellular
conductance through a selective decrease in sodium permeability. J
Clin Invest. 107:1319–1327. 2001. View
Article : Google Scholar
|
|
29
|
Montagner A, Yart A, Dance M, Perret B,
Salles JP and Raynal P: A novel role for Gab1 and SHP2 in epidermal
growth factor-induced Ras activation. J Biol Chem. 280:5350–5360.
2005. View Article : Google Scholar : PubMed/NCBI
|
